Biblio Discovery — Demo Discovery Service

8 results for "Ferguson, Deborah A."

Showing 1–8 · 6.29 seconds · RSS

  1. Journal Article Full text

    Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405

    Probst, Brandon L.; McCauley, Lyndsey; Trevino, Isaac et al.

    PLoS One · 2015 · English · PubMed Central

    Synthetic triterpenoids are antioxidant inflammation modulators (AIMs) that exhibit broad anticancer activity. AIMs bind to KEAP1 and inhibit its ability to promote NRF2 degradation. As a result, NRF2 increases transcription of genes that restore redox balance and reduce inflammation. AIMs inhibit…

  2. Journal Article Full text

    Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitis

    Reisman, Scott A.; Ferguson, Deborah A.; Lee, Chun‐Yue I. et al.

    J Biochem Mol Toxicol · 2020 · English · PubMed Central

    Omaveloxolone is a potent activator of Nrf2, a master transcriptional regulator of a multitude of cytoprotective functions, including antioxidative, anti‐inflammatory, and mitochondrial bioenergetic effects. Some of the most potent known effects of Nrf2 involve hepatoprotective functions. The…

  3. Journal Article Full text

    Evaluating the potential of Vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide

    Lebreton, Sylvain; Jaunbergs, Janis; Roth, Michael G. et al.

    Bioorg Med Chem Lett · 2008 · English · PubMed Central

    The natural product salicylihalamide is a potent inhibitor of the Vacuolar ATPase (V-ATPase), a potential target for antitumor chemotherapy. We generated salicylihalamide-resistant tumor cell lines typified by an overexpansion of lysosomal organelles. We also found that many tumor cell lines…

  4. Journal Article Full text

    RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity

    Probst, Brandon L.; Trevino, Isaac; McCauley, Lyndsey et al.

    PLoS One · 2015 · English · PubMed Central

    Semi-synthetic triterpenoids are antioxidant inflammation modulator (AIM) compounds that inhibit tumor cell growth and metastasis. Compounds in the AIM class bind to Keap1 and attenuate Nrf2 degradation. In the nucleus, Nrf2 increases antioxidant gene expression and reduces pro-inflammatory gene…

  5. Journal Article Full text

    The synthetic triterpenoid, RTA405, increases glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells

    Ding, Yanfeng; Stidham, Rhesa; Bumeister, Ron et al.

    Kidney Int · 2012 · English · PubMed Central

    Bardoxolone methyl, a synthetic triterpenoid, improves the estimated glomerular filtration rate (GFR) in patients with chornic kidney disease and type 2 diabetes. Since the contractile activity of mesangial cells may influence glomerular filtration, we evaluated the effect of the synthetic…

  6. Journal Article Full text

    Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1

    Wu, Qing Qing; Wang, Yanxia; Senitko, Martin et al.

    Am J Physiol Renal Physiol · 2011 · English · PubMed Central

    Ischemic acute kidney injury (AKI) triggers expression of adaptive (protective) and maladaptive genes. Agents that increase expression of protective genes should provide a therapeutic benefit. We now report that bardoxolone methyl (BARD) ameliorates ischemic murine AKI as assessed by both renal…

  7. Journal Article Full text

    Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD

    Lewis, James H.; Jadoul, Michel; Block, Geoffrey A. et al.

    Clin Transl Sci · 2020 · English · PubMed Central

    In a multinational placebo‐controlled phase III clinical trial in 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, treatment with the Nrf2 activator bardoxolone methyl increased estimated glomerular filtration rate, a measure of kidney function, but also resulted in…

  8. Journal Article Full text

    A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

    Hong, David S.; Kurzrock, Razelle; Supko, Jeffrey G. et al.

    Clin Cancer Res · 2012 · English · PubMed Central

    PURPOSE: Bardoxolone methyl, a novel synthetic triterpenoid and antioxidant inflammation modulator, potently induces Nrf2 and inhibits NF-κB and Janus-activated kinase/STAT signaling. This first-in-human phase I clinical trial aimed to determine the dose-limiting toxicities (DLT), maximum tolerated…